CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of multiple myeloma.
  
  LEARNING OBJECTIVES

  • Customize the selection of first-line therapy for newly diagnosed MM, considering new clinical research findings and patient- and disease-related factors, including cytogenetic profile and fitness for stem cell transplantation.
  • Appreciate trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory MM.
  • Understand the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
  • Evaluate the biological rationale for and published research information with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
  • Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with or participation in a clinical trial of one of these novel agents would be appropriate.
  • Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in clinical trials.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMM24/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASHMM24/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHMM24/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASHMM24.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Professor Philippe Moreau, MD
  Professor of Clinical Hematology
  Head of the Translational Research Program
  Hematology and Oncology
  University Hospital ­– CHU de Nantes
  Nantes, France
  
  Advisory Committees: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, GSK, Janssen Biotech Inc, Pfizer Inc, Sanofi.
  
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Vice Chair, Myeloma Translational Research
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committees: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, IASO Bio, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, CARsgen Therapeutics, Exelixis Inc, Heidelberg Pharma, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, Biotheryx, Heidelberg Pharma; Patent: Asylia Therapeutics Inc.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Caribou Biosciences Inc, Immuneel Therapeutics; Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Janssen Biotech Inc, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio.
  
  Paul G Richardson, MD
  Clinical Program Leader and Director of Clinical Research
  Jerome Lipper Multiple Myeloma Center
  Dana-Farber Cancer Institute
  RJ Corman Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Oncopeptides.
  
  MODERATOR
  Sagar Lonial, MD
  Chair and Professor
  Department of Hematology and Medical Oncology
  Anne and Bernard Gray Family Chair in Cancer
  Chief Medical Officer
  Winship Cancer Institute
  Emory University School of Medicine
  Atlanta, Georgia
  
  Advisory Committees and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis; Stock Options/Stock — Public Company: TG Therapeutics Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.
  
  Release date: December 2024
  Expiration date: December 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.